Interleukin-1 Synergy with Phosphoinositide Pathway Agonists for Induction of Interleukin-2 Gene Expression: Molecular Basis of Costimulation by Novak, Thomas J. et al.
Vol. 10, No. 12
Interleukin-1 Synergy with Phosphoinositide Pathway Agonists for
Induction of Interleukin-2 Gene Expression: Molecular
Basis of Costimulation
THOMAS J. NOVAK,t DAN CHEN, AND ELLEN V. ROTHENBERG*
Division ofBiology, California Institute of Technology, Pasadena, California 91125
Received 4 June 1990/Accepted 24 August 1990
The macrophage-derived cytokine interleukin-1 (IL-1) can provide a second signal with antigen to elicit
production of interleukin-2 (IL-2) by helper T cells. The pathway(s) involved remains controversial, with
protein kinase C and cyclic AMP (cAMP) invoked as possible second messengers. In the murine thymoma
EL4.E1, IL-1 could synergize with the phosphoinositide pathway, because the cells made higher levels of IL-2
in the presence of IL-1 than could be induced by phorbol ester plus calcium ionophore alone. IL-1 is unlikely
to act through a sustained increase in cAMP in these cells because it did not raise cAMP levels detectably and
because IL-1 and forskolin had opposite effects on IL-2 gene expression. Inducible expression of a transfected
reporter gene linked to a cloned fragment of the murine IL-2 gene promoter was initially increased by IL-1
costimulation, implying that IL-1 can increase the rate of transcription of IL-2. The minimal promoter
elements required for IL-1 responsiveness were located within 321 bp of the IL-2 RNA cap site, and further
upstream sequences to -2800 did not modify this response. IL-1 costimulation resulted in enhanced activity of
both an inducible NF-KB-like factor and one of two distinct AP-1-like factors that bind to IL-2 regulatory
sequences. Neither was induced, however, by IL-1 alone. Another AP-1-like factor and NFAT-1, while
inducible in other cel types, were expressed constitutively in the EL4.E1 cells and were unaffected by IL-1.
These results are discussed in terms of the combinatorial logic of IL-2 gene expression.
Interleukin-1 (IL-1) is a potent mediator of cellular func-
tion that is produced primarily by activated macrophages
(19), and a role for IL-1 in T-cell activation has been
demonstrated in a number of experimental systems (7, 8, 25).
In vitro, IL-1 synergizes with mitogenic lectins or anti-T-cell
receptor (TcR) antibodies to induce expression of interleukin
2 (IL-2) and IL-2 receptor a-chain genes (13, 18, 44). In these
roles, IL-1 can be replaced by tumor-promoting phorbol
esters (e.g., 12-0-tetradecanoylphorbol 13-acetate [TPA])
(11). As IL-1 was known to provide a necessary, antigen-
nonspecific signal for T-cell activation (9), this apparent
equivalence with TPA initially suggested that its action
might result from activation of protein kinase C (28). How-
ever, IL-1 does not promote phosphoinositide hydrolysis or
cause protein kinase C translocation to an active membrane-
bound form (1). It therefore seems unlikely that its role is to
augment the low levels of diacylglycerol produced by TcR-
mediated phosphoinositide breakdown. More recently, it has
been demonstrated that IL-1 treatment of the human T-cell
leukemia line Jurkat causes increased production of two
protein kinase C cofactors, phosphatidylserine and diacyl-
glycerol, the latter from hydrolysis of membrane phosphati-
dylcholine (23, 34). However, because Jurkat lacks conven-
tional IL-1 receptors (IL-lRs) (34), the significance of these
results for other T cells is unknown.
The studies that have reported a costimulatory role for
IL-1 have usually demonstrated this effect on cells subopti-
mally stimulated with mitogenic lectins (13, 15, 18, 44).
Several laboratories have obtained results that call into
doubt the notion that IL-1 is necessary at all for the
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high-level production of IL-2 when the TcR signal is opti-
mized. We have shown that when fresh splenic T cells
produce IL-2 in response to TPA and the calcium ionophore
A23187, their response is both independent of and insensi-
tive to added IL-1 (35, 36). Lichtman et al. (21) have
obtained similar results with a panel of cloned antigen-
dependent THi cell lines stimulated with an anti-CD3 mono-
clonal antibody. Two other groups have shown that long-
term TH1 (IL-2-producing) lines may lack IL-iRs altogether
(14, 20). Thus, these systems do not provide access to any
unique pathway through which IL-1 may act.
Recent data suggest, however, that a requirement for IL-1
may reflect the developmental status of a T cell. These
differences are most apparent in induction of IL-2 expression,
a response subject to complex regulation (16, 27, 32). Mature
TcR+ thymocytes resemble peripheral T cells in their insen-
sitivity to IL-1 when they are stimulated to produce IL-2 in
response to TPA plus A23187. These chemical proxies for
mediators of the phosphatidylinositol bisphosphate hydroly-
sis pathway may be able to induce IL-2 expression in all
mature T cells, for they can also elicit high-level responses in
most fresh peripheral CD8+ cells (24), cells which generally
do not express IL-2 mRNA in response to either antigen or
mitogenic lectins. In contrast, however, immature TcR-
double-negative thymocytes do not make IL-2 in response to
TPA and A23187 at all unless IL-1 is present (35, 36). Thus,
these immature thymocytes differ from their more mature
descendents in two important aspects of their IL-2 inductive
signal requirements. First, in these cells, phosphoinositide
pathway agonists are insufficient to activate IL-1 expression.
Second, they possess a pathway allowing IL-1 effects to
synergize with phosphoinositide pathway mediators.
Here we report that the cloned murine thymoma EL4.E1
possesses characteristics of both immature and mature IL-2
producers. Like mature T cells, it can respond to phorbol
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ester and ionophore alone. In addition, it possesses a trait
normally associated with immature thymocytes, namely,
responsiveness to IL-1 as a costimulus with TPA plus
A23187. We have used these cells to explore the mechanism
by which the synergy between IL-1 and TPA plus A23187
occurs.
MATERIALS AND METHODS
Reagents. TPA and A23187 were from Sigma or Calbio-
chem. They were dissolved in dimethyl sulfoxide to final
concentrations of 10 ,ug/ml and 0.37 mg/ml, respectively, and
stored in small samples at -20°C. Recombinant human and
mouse IL-la (IL-1) was purchased from Genzyme. The
specific activity, as reported by the supplier, was 108 U/mg.
Cells. EL4.E1, a mouse IL-2-producing thymoma cell line
(originally donated by V. Paetkau, University of Alberta),
and the human T-cell leukemic line Jurkat (generously
provided by G. Crabtree, Stanford University) were grown
in RPMI 1640 supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 50 p.M 2-mercaptoethanol, and antibiotics.
Plasmids. The series of pIL2-CAT plasmids containing
varying lengths of the mouse IL-2 gene 5' DNA linked to the
bacterial gene for chloramphenicol acetyltransferase (CAT)
has been described in detail (30). Briefly, cloned fragments
of the IL-2 gene 5'-flanking region, all terminating 3' at +45
(in the 5' untranslated region), were ligated to the CAT gene
from pTK-CAT in the vector pSP65 (Promega). They are
designated pIL2(-X), where X is the 5'-terminal nucleotide,
relative to the IL-2 transcriptional start site, that is present in
the construct. All plasmids were purified in CsC1-ethidium
bromide density gradients before use.
Transfections and CAT assays. Transfection of logarithmi-
cally growing cells was by DEAE-dextran facilitation as
described elsewhere (30). In short, cells were washed in
serum-free Dulbecco modified Eagle medium with 10 mM N-
2-hydroxylethylpiperazine-N'-2-ethanesulfonic acid (HEPES;
pH 7.0) (DME/H) and then suspended at 107/ml in a trans-
fection cocktail containing 250 ,ug of DEAE-dextran (molec-
ular weight, 2 x 106) per ml, 0.1 mM chloroquine, and 10 ,ug
of supercoiled plasmid DNA per ml, all in DME/H. After
incubation for 30 to 60 min at 37°C in 7% C02, cells were
pelleted, washed, and plated into 4 to 12 identical cultures.
Approximately 20 h after plating, cells were stimulated with
TPA and A23187 at final concentrations of 10 and 37 ng/ml,
respectively. These dosages were previously determined to
be optimal for both IL-2 mRNA expression and secretion
over 18 to 20 h in the population overall. Some ofthe cells also
received IL-1 to the indicated concentrations. Human recom-
binant IL-la was found to be as effective as the mouse
version on ELA.E1 cells and was used in most experiments.
Cells were harvested after various times of stimulation,
and extracts from equivalent numbers of cells were assayed
for CAT activity in a 5-h assay as described previously (29).
RNA analysis. Cytoplasmic RNA was extracted by the
method of Favaloro et al. (12). The RNA from equivalent
cell numbers was electrophoresed in denaturing 1% agarose-
formaldehyde gels, stained with acridine orange to visualize
the rRNA, and then blotted onto nylon membranes (Nytran;
Schleicher & Schuell). The RNA was fixed to the membrane
by baking at 80°C for 60 min. Hybridization probes were
generated by random priming of cDNAs for mouse IL-2 (46)
and mouse skeletal a-actin (S. Sharp and N. Davidson,
unpublished data) as described elsewhere (30). Hybridiza-
tions were carried out for 20 h at 42°C in 5 x SSPE-50%
formamide-0.2% sodium dodecyl sulfate (SDS)-5 x Den-
hardt solution-10% dextran sulfate. Filters were washed three
times at room temperature for 1 min each in 2x SSC(SSC is
0.15 M NaCl prus 0.015 M sodium citrate-0.2% SDS-0.05%
sodium pyrophosphate, followed by two 30-min washes at
680C in 0.2x SSC-0.1% SDS-0.05% sodium pyrophosphate.
Filters were exposed to film at -700C with an intensifying
screen, and autoradiograms in the linear response range were
densitometrically scanned. The amount of IL-2 mRNA was
normalized with respect to the actin signal.
cAMP determination. EL4.E1 cells were resuspended in
medium at a concentration of 1.2 x 106/ml and were stimulated
at 37°C as indicated in Table 2. Cell extracts were assayed for
cyclic AMP (cAMP) by using a competition binding assay
(RPA.509; Amersham) as described elsewhere (T. J. Novak
and E. V. Rothenberg, Proc. Natl. Acad. Sci. USA, in press).
Extracts were acetylated before assay to increase sensitivity.
Nuclear extracts. Nuclear proteins were extracted accord-
ing to published procedures (6, 8; G. Crabtree, personal
communication) from cells that had been stimulated for 3 to
4 h under the conditions described for Fig. 4 and Table 3.
Proteins extracted by either method gave similar results in
gel mobility shift assays, and the data presented in Table 4
were obtained by using both types of extraction protocols.
Extracts were stored at -80°C until use.
Gel mobility shift assay. Mobility shift assays were carried
out essentially as described elsewhere (3), with minor mod-
ifications. Synthetic double-stranded oligonucleotides were
end labeled by filling in with either 35S- or 32P-labeled dTTP
and dATP. For binding assays, 2.5 to 5.0 ,ug of nuclear
protein was incubated for 15 min at 250C with -0.1 ng of
probe in the presence of a nonspecific competitor, usually
0.5 jig of poly(dI - dC) for NF-KB, 0.25 to 0.5 p.g of poly(dIdC) for AP-1D and AP-1p, or 2.5 to 10 ,ug of poly(dA * dT)
for NFAT-1.
Complexes were separated from free probe by electropho-
resis through 8% acrylamide gels which were cast and run in
low-ionic-strength buffer. Gels were dried and exposed to
film at -70°C with intensifying screens. For experiments
with 35S-labeled probes, gels were fixed in Amplify (Amer-
sham) and complexes were detected by fluorography.
For competition binding studies, 2.5 to 5.0 p.g of nuclear
extract was preincubated for 15 min at 25°C with the
indicated molar excess of competitor DNA (either a syn-
thetic oligonucleotide or a cloned genomic fragment) before
addition of labeled probe.
The synthetic oligonucleotides contained the binding sites
for NFAT-1, NF-KB, AP-1P and AP-1D as found upstream of
the mouse IL-2 gene (30) and were of the following se-
quences (coding strands on top):
AP-1 consensus
(Stratagene)
AP-lp
AP-iD
NF-KB
NFAT-1
5'-CTAGTGATGAGTCAGCCGGATC-3'
5'-GATCCGGCTGACTCATCAGTAG-3'
5'-AATTCCAGAGAGTCATCAG-3'
5'-CTGATGACTCTCTGG-3'
5'-AAATCCATTCAGTCAGTG-3'
5'-CACTGTCTGAATGG-3'
5'-AAGAGGGATTTCACCT-3'
5'-ATTTAGGTGAAATCCCTCTT-3'
5'-AAGAGGAAAATTTGTTTCATACAGAAGGCG-3'
5'-AATTCGCCTTCTGTATGAAACAAATTTTCCTCTT-3'
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TABLE 1. Effects of different stimuli on IL-2 production by
EL4.EI cells
IL-2 titer (UIml)b
Stimulationa
Expt 1 Expt 2
None <4 <4
TPA 256 386
IL-1 <4 <4
TPA + A23187 307 448
TPA + A23187 + IL-1 1,280 614
TPA + A23187 + forskolin 106 204
a Cells were incubated for 20 h in the presence or absence of TPA (35 nM),
A23187 (140 nM), IL-1 (20 U/ml), and forskolin (10 FLM). Confirmation of the
inhibitory effects of forskolin at the RNA level is presented by Novak and
Rothenberg (in press).
b Titer in supernatants, determined by colorimetric assay on CTLL-2 cells
as previously described (36). The presence of IL-1 in the assay supematants
has no effect on the indicator cells (36), and the addition of forskolin did not
interfere with the quantitative detection of IL-2 in a control experiment (after
adjustment to 10 pLM forskolin, a sample with 450 U of IL-2 per ml gave a titer
of 530 U of IL-2 per ml in this assay; E. V. Rothenberg, unpublished data).
RESULTS
IL-1 is a costimulus for IL-2 expression by phorbol ester-
and ionophore-treated EL4.E1 cells. The EL4.E1 thymoma is
a convenient murine model for studies of IL-2 gene expres-
sion, but it differs from normal THi cells in several ways.
First, it is responsive to TPA alone. A Ca2+ costimulus
elicits higher levels of IL-2 but is not required. Second,
unlike normal mature T cells (35), it shows synergy between
IL-1 and TPA + A23187. These features are illustrated in
Table 1, which presents typical yields of IL-2 from EL4.E1
cells after 20 h of stimulation under different conditions. The
addition of calcium ionophore generally increased the levels
of IL-2 relative to those elicited by TPA alone, to a maxi-
mum level that could not be surpassed by increasing the
doses of TPA + A23187 (data not shown). The further
addition of IL-1, however, resulted in even higher levels of
IL-2 secretion. Nevertheless, IL-1 alone did not stimulate
any detectable production of IL-2. Thus, the effect of IL-1 in
these cells was to potentiate the effects of the TPA and
A23187 stimuli on IL-2 synthesis. Such a potentiation could
operate at pretranscriptional, posttranscriptional, or post-
translational levels. To dissect the basis for these differences
in cumulative IL-2 synthesis over 20 h, we examined the
time course of IL-2 RNA accumulation.
The accumulation of IL-2 transcripts in EL4.E1 cells
stimulated with TPA + A23187 alone was rapid and bimodal
(Fig. 1A, lanes 2, 6, and 10). IL-2 mRNA levels peaked
around 5 h and declined slowly during the next 13 h.
Costimulation of EL4.E1 cells with 2.5 or 20 U of IL-1 per
ml resulted in a two- or sixfold increase, respectively, in IL-2
mRNA at 5 h (Fig. 1A, lanes 1 to 4). This effect was primarily
observed at early times of stimulation. At 12 h the enhance-
ment due to IL-1 was only 1.5-fold (Fig. 1A, lanes 6 to 9),
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FIG. 1. IL-1 costimulation of IL-2 induction: effects on the IL-2 promoter. (A) Gel blot of cytoplasmic RNA extracted from unstimulated
or stimulated EL4.E1 cells. Cells were stimulated as indicated for 5 to 18 h, and RNA from 106 cells was extracted, electrophoresed on a
denaturing 1% agarose-formaldehyde gel, transferred to a nylon membrane (Nytran), and hybridized to cDNA probes for IL-2 and skeletal
a-actin. (B) CAT assay of extracts from EL4.E1 cells transfected with pIL2(-2800). Cells were stimulated as for panel A. Each lane
represents the extract from transfected cells stimulated under conditions identical to those of the sample used for the corresponding lane of
the RNA gel blot. Extracts were assayed at 37°C for 5 h. Lanes 13 and 14 represent negative and positive assay controls, respectively. Positive
control contains commercial CAT enzyme. [C], Unacetylated chloramphenicol; [CA], monoacetylated chloramphenicol.
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FIG. 2. Normalized time courses of IL-2-CAT expression in the presence or absence of recombinant IL-la. (A) Time courses for EL4.E1
cells transfected with pIL2(-321), pIL2(-1890), and pIL2(-2800). Calculations for each plasmid were done separately. Each experiment
consisted of six datum points: 5 h, 12 h (data not shown), and 18 h stimulated ± 20 U of human recombinant IL-la per ml. CAT activity per
106 cells was normalized with respect to the highest value in that experiment (in all but one case this was the 18-h sample without IL-1).
Results are the means ± standard errors of the mean of two to five separate experiments except for the pIL2(-1890) 5-h values, which were
determined in one time course. (B) Normalized CAT assay curve for transfected Jurkat cells. Experimental conditions and calculations were
exactly as for panel A. Open symbols, pIL2(-321); closed symbols, pIL2(-2800). Data are from one experiment.
and by 18 h IL-1 ceased to augment the level of steady-state
IL-2 mRNA (Fig. 1A, lanes 9 to 12). The early increase and
later loss of IL-2 RNA makes it likely that IL-1 costimulation
increases the transcription rate but not RNA stability or
translational efficiency.
No IL-2 mRNA was detected when EL4.E1 cells were
stimulated for 5 h with 20 U of IL-1 per ml in the absence of
TPA, alone or in combination with 37 ng of A23187 per ml
(not shown). This inability to respond to IL-1 plus ionophore
is in contrast to results reported by others for several
IL-1-independent cell lines (43, 47), possibly because of the
lower concentration of ionophore used here (37 ng/ml = 70
nM, compared with 250 to 500 nM). The failure of IL-1 to
substitute for TPA suggests that it cannot duplicate the
effects of TPA on protein kinase C.
Costimulatory effects of IL-1 are mediated through the IL-2
gene promoter. To determine whether the IL-2 gene pro-
moter was responsible for mediating this positive effect, we
used a series of pIL2-CAT plasmids that contains various
lengths of IL-2 5'-flanking DNA, including the transcrip-
tional start site, driving expression of CAT (30). In this way
we could assay transcriptional initiation without concern for
regulatory variations in mRNA stability (22) since, unlike
authentic IL-2 mRNA, the CAT 3' untranslated region does
not contain the AUUUA motifs that target lymphokine
transcripts for rapid degradation (33, 38). Note that the CAT
assay measures the translation product of the induced RNA,
not the RNA directly.
Transfection experiments using IL2-CAT plasmids sug-
gest that IL-1 can increase the rate of transcription from the
IL-2 gene promoter, even in cells optimally stimulated with
TPA and ionophore. Several pIL2-CAT plasmids were trans-
fected into EL4.E1 cells along with pRSV-CAT as a positive
control. CAT activity was measured after 5, 12, and 18 h of
stimulation with TPA and A23187 in the presence and
absence of IL-1 (Fig. 1B and 2). A CAT assay of cells
transfected with pIL2(-2800) is shown in Fig. 1B. Expres-
sion of the transfected IL-2-CAT gene required an appropri-
ate inductive signal because unstimulated cells contained no
enzyme activity (Fig. 1B, lanes 1, 5, and 9). Thus, even when
introduced as a naked DNA template, the IL-2 gene pro-
moter was not promiscuously transcribed in these cells.
EL4.E1 transfectants stimulated with TPA plus A23187
contained easily detectable CAT activity at 5 h (Fig. 1B, lane
2), which would be expected if the peak in endogenous IL-2
mRNA seen at this time resulted from transcriptional acti-
vation of the IL-2 gene promoter. CAT activity in these cells
continued to rise over the next 13 h, reaching a maximum at
18 h, the latest time examined. This increase in CAT activity
occurred even as the steady-state level of endogenous IL-2
mRNA dropped (Fig. 1A), possibly indicating greater stabil-
ity of the IL-2-CAT mRNA.
The addition of IL-1 to the stimulation regimen had two
dramatic effects. First, cells stimulated in the presence of
IL-1 contained up to 2.5 times as much CAT activity per cell
at 5 h as did those stimulated with TPA and A23187 alone
(Fig. 1B, lanes 1 to 4, and Fig. 2A). This effect was IL-1 dose
dependent because the enhancement was greater with 20
than with 2.5 U/ml.
Second, the increase was transient, like the effect on
endogenous IL-2 mRNA. Not only did IL-1 completely
cease to enhance the steady-state level of IL-2 mRNA at 18
h (Fig. 1A, lanes 10 to 12), it also ceased to increase the
amount of CAT activity per cell. In fact, CAT activity
induced in the presence of IL-1 was now at least 60 to 70%
lower than in cells stimulated without IL-1 (Fig. 2A). The
mechanism of this late decrease is not fully understood but
may be nonspecific. At 18 h, the positive control plasmid,
pRSV-CAT, was also expressed at levels 31% lower in cells
costimulated with IL-1 than in cells stimulated without IL-1
L.
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TABLE 2. Failure of IL-1 to increase cAMP in stimulated
EL4.E1 cells
cAMP concn
Stimulation Time (fmol/106 cells)b
conditionsa (min)
Expt 1 Expt 2
No stimulation 350 320
TPA + A23187 15 300 320
30 250 310
60 271 380
TPA + A23187 + 20 U of IL-1/ml 15 246 300
30 308 340
60 258 460
TPA + A23187 + 10-7 M forskolin 15 ND 460
30 ND 470
60 ND 750
TPA + A23187 + 10-5 M forskolin 15 ND >4,000
30 ND >4,000
60 ND >4,000
a EL4.E1 cells were stimulated with TPA (10 ng/ml) + A23187 (37 ng/ml) at
a density of 1.2 x 106/ml.
b Measured by using a commercial assay kit as described in Materials and
Methods. All values are from assays with acetylated standards and samples.
The high values for samples with 10'5 M forskolin were corroborated by
reassay with nonacetylated standards and samples. ND, Not done.
(see below and Table 3). By contrast, the early enhancement
of CAT expression from the IL-2 gene promoter was pro-
moter specific. Expression of pRSV-CAT in stimulated
EL4.E1 cells was not affected by the presence of IL-1 when
examined after 3 or 5 h of stimulation (unpublished data).
This result suggests that at later times, IL-1 caused a general
decrease in CAT expression, possibly via reduced transla-
tional efficiency, which was distinct from its promoter-
specific transcriptional enhancing effects seen at 5 h.
Possible mediators contributing to the effects of IL-1 on
EL4.E1 cells. (i) IL-1R. The effects of IL-1 on the IL-2 gene
promoter require the expression of IL-1R, as demonstrated
by the results from identical transfection experiments using
IL-1R- Jurkat cells instead of EL4.E1 cells. A time course
of IL-2-CAT expression in Jurkat cells is shown in Fig. 2B.
These cells showed much slower kinetics of expression of
pIL2-CAT plasmids than did EL4.E1 cells. No activity was
detected at 5 h even in the presence of 20 U of IL-1 per ml.
Cells had begun to express by 12 h, and CAT activity was
still rising by 18 h. However, no significant effect, early or
late, could be attributed to IL-1. These results provide
evidence that surface expression of a canonical IL-1R is a
prerequisite for the IL-1 effects that we have described. It is
thus unlikely that the effects seen in EL4.E1 cells are due to
the type of phosphatidylcholine hydrolysis reported to occur
in Jurkat cells (34).
(ii) cAMP. It has been shown that IL-1 can utilize cAMP as
an intracellular second messenger in a number of non-T-cell
lines (42). Our results argue against a simple cAMP elevation
mechanism as the pathway for IL-1 costimulation in EL4.E1
cells. First, IL-1 costimulation had minimal effects on cAMP
levels in these cells (Table 2). Second, the effects of 20 U of
IL-1 per ml and 10 ,uM forskolin were clearly different (Table
3). Expression of pRSV-CAT was enhanced at 18 h with
forskolin but inhibited with the concentration of IL-1 used
here. Whereas expression of pIL2(-321) was depressed at
18 h by both IL-1 and forskolin, the 5-h results clearly
demonstrated the dissimilarity of these two stimuli. Forsko-
TABLE 3. Distinct effects of IL-1 and forskolin on expression of
pRSV-CAT and plL2(-321) in EL4.E1 cells
Stimulation CAT activity (% of control)a
Construct time +IL-1 +10 FM
(h) (20 U/ml) forskolinb
pRSV-CAT 18 68 ± 0.5 427 ± 99
pIL2(-321) 5 169 ± 22 28 ± 4
18 43 6 51 17
a Cells were stimulated for the indicated lengths of time with TPA (10 ng/ml)
+ A23187 (37 ng/ml) in the presence or absence of IL-1 or forskolin. CAT
activity per 106 cell equivalents was determined, and the value for the
drug-treated samples was normalized with respect to that of the drug-free
control. Results are presented as means + standard errors of the mean or as
means + ranges (in the cases with two experiments) of two to four experi-
ments each.
b Results are presented in more detail elsewhere (Novak and Rothenberg, in
press).
lin was even more suppressive at 5 h than at 18 h, whereas
IL-1 was stimulatory at this time point (Table 3; see also Fig.
1B, lanes 1 to 4, and Fig. 2A). We have also shown that
elevation of cAMP by a variety of other agents can depress
IL-2 gene expression in a dose-dependent fashion (Novak
and Rothenberg, in press), supporting the conclusion that
elevation of cAMP levels per se has a net negative effect on
IL-2 gene promoter function. While these results do not rule
out cAMP-responsive signaling molecules as participants in
the IL-1 enhancement pathway, they do show that the
stimulatory effect of IL-1 is unlikely to be a result of any
sustained increase in cAMP concentration.
IL-2 gene promoter sequences upstream of -321 are not
required for IL-1 costimulation. Our previous work on the
upstream region of the mouse IL-2 gene indicated the
presence of several positive and negative regulatory ele-
ments between -321 and -2800, any of which might be
involved in IL-1-mediated effects. However, the data pre-
sented in Fig. 2A make it unlikely that far-upstream se-
quences are required.
When normalized for maximal levels of CAT activity, the
kinetics of IL-1 costimulation for pIL2(-321), pIL2(-1890),
and pIL2(-2800) were virtually superimposable (Fig. 2A).
Thus, the degrees of both the 5-h enhancement and the 18-h
suppression were unaffected by IL-2 5'-flanking sequences
extending upstream of -321. It should be noted, however,
that the absolute amount of CAT activity per cell at each
time point was higher with pIL2(-1890) and pIL2(-2800)
than with pIL2(-321), in accord with our previously re-
ported results (30).
Further truncation of the IL-2 gene promoter region led to
severe loss of inducibility, such that any IL-1-dependent
enhancement was difficult to detect. We evaluated the re-
sponses of two plasmids with deletions in the region from
-321 to -261. One, pIL2(-232), failed to give significant
expression with or without IL-1 at any time point. Expres-
sion of the other, pIL2(-1890; ANFAT-1), which bears a
deletion from -261 to -321 (30), was also undetectable at 5
h of stimulation, when IL-1 would be expected to exert a
positive effect (P. M. White, T. J. Novak, and E. V.
Rothenberg, unpublished results; 30). Thus, retention of
sequences between -261 and -321 appeared to be essential
for expression and IL-1 costimulation.
Effect of IL-1 costimulation on sequence-specific DNA-
binding factors. The sequences from -50 to -300 in the
human IL-2 gene include binding sites for several DNA-
binding proteins of different specificities which have been
implicated in regulation (4, 10). One factor, binding se-
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FIG. 3. Specificities of complexes with binding activity for IL-2 regulatory sequences. (A) Homologous and heterologous competition for
the complex binding the NFAT-1 oligonucleotide. Competition gel shift assays were carried out as described in Materials and Methods with
a labeled NFAT-1 oligonucleotide. Unlabeled competitor oligonucleotides were added as indicated, to 50- to 200-fold molar excesses. The
arrow indicates the specific NFAT-1 complex. (P) and (D) represent the AP-1P and AP-1D oligonucleotides, respectively. Lane 1, No specific
competitor. Each lane contained 2.5 ,ug of nuclear extract from cells stimulated with TPA + A23187 + IL-1 with 2.3 ,ug of poly(dA dT) as
nonspecific competitor. (B) As panel A, using labeled NF-KB oligonucleotide with the indicated competitors at the molar excesses shown.
Lane 1, No specific competitor. (- 148/-217) is a restriction fragment from the natural IL-2 gene promoter that contains the NF-KB site. Its
greater potency as a competitor in part reflects a general effect of length (F. J. Calzone and E. H. Davidson, personal communication). Each
lane contained 5 jig of extract from TPA + A23187-stimulated cells and 0.5 jig of poly(dI dC). (C) Cross-competition of complexes binding
the AP-1p and AP-1D oligonucleotides. Lanes: 1 to 7, AP-1p probe with the indicated competitors (lane 7, no specific competitor); 8 to 14,
AP-1D probe with the indicated competitors (lane 8, no specific competitor). (A) denotes a commercial consensus AP-1 22-mer (Stratagene),
used at 50-fold molar excess; (N) denotes the NF-KB oligonucleotide used at 200-fold molar excess. Arrows indicate the mobilities of the main
AP-1p complex (left) and the AP-1D complex (right). Each lane contained 5 jig of extract as in panel A, with 0.125 jig of poly(dI dC). Both
extracts used in this figure were made by the method of Dignam et al. (6).
quences from -66 to -90, is the constitutive Oct-1 protein,
which also appears to bind sequences between -240 and
-250 (10). Factors whose binding activity is known to be
dependent on cellular activation bind at -264 to -284
(NFAT-1) and -196 to -205 (NF-KB or a close relative) (5,
17, 39). In addition, there are two potential sites for the
binding of the canonical TPA-response factor AP-1 (2),
although neither contains a perfect consensus sequence.
One, from -186 to -195 (AP-1D), has been proposed as a
critical site for IL-1 effects in another cell line (26). The
other, from -145 to -153 (AP-1p), has been shown to bind
a purified AP-1 factor (37).
To dissect the mechanism of IL-1 costimulation of EL4.E1
cells, we focused on the four sites for potentially inducible
factors: NFAT-1, NF-KB, AP-1D, and AP-1p. Synthetic
double-stranded oligonucleotides containing these sites as
found in the murine IL-2 gene were used in gel retardation
assays to detect DNA-binding proteins in nuclear extracts
from EL4.E1 cells after different types of stimulation. Typ-
ical results, representative of four to seven independent
analyses, are presented in Fig. 3 and 4. A summary is
provided in Table 4.
Four distinct binding specificities. Confirmation of the
distinct specificities of these factors is presented in Fig. 3.
The binding of NFAT-1 was highly sensitive to competition
with its homologous target sequence and impervious to
competition with the other oligonucleotides used (Fig. 3A).
Figure 3B similarly confirms the specificity of the NF-KB
complexes and their ability to be competed for by a longer
IL-2 DNA fragment (-148 to -217) that contains this site.
We routinely observed a doublet of complexes binding the
NF-KB site, both of which appear specific by competition
analysis. Only the upper band was strongly induction depen-
dent, however, and in the text that follows we will use
"NF-KB" to refer only to this slower-migrating species.
The factors that bind to the two AP-1 sites are not
identical, although their target sites are of related sequence.
This conclusion was confirmed by the cross-competition
analysis shown in Fig. 3C. First, the two complexes had
different mobilities (compare lanes 7 and 8). Second, it is
clear that they had different binding preferences. Both were
legitimately capable of binding a commercial consensus
AP-1 oligonucleotide (Fig. 3C, lanes 5 and 13), and neither
was detectably competed for by the NF-KB site oligonucle-
otide (lanes 6 and 14). However, while the AP-1P oligonu-
cleotide competed for the complex binding its homologous
sequence (lanes 1 and 2), it did not compete for the AP-1D
complex (lanes 9 and 10). Correspondingly, the AP-1D
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FIG. 4. Differential activation of IL-2 DNA-binding factors under different conditions of stimulation. In each panel, the indicated probes
were used for gel shift analysis, each lane containing 5 jig of extract from EL4.E1 cells that were stimulated for 3.5 h under the indicated
conditions: U, unstimulated; T, TPA alone; I, IL-1 alone; T/A, TPA plus A23187; T/A+I, TPA plus A23187 plus IL-1; T/A+F, TPA plus
A23187 plus 10 FjM forskolin. In panel A only, NFAT-1 complexes from EL4.E1 cells (lanes 3 to 9) are compared with complexes formed
by nuclear extracts from Jurkat cells, either unstimulated (U) or stimulated with TPA plus A23187 (S). (A) NFAT-1 factor. The arrow
indicates the NFAT-1 complex, which is inducible in Jurkat cells (lanes 1 and 2) but constitutive in EL4.E1 cells (lanes 4 to 9). Lane 3 contains
a duplicate of the extract used in lane 6 with a lower amount of nonspecific competitor, to demonstrate that the lower band seen in the Jurkat
sample (lane 1) is nonspecific. (B) NF-KB factors. The arrow indicates the upper complex, which is more strictly dependent on induction than
the lower complex and which is the subject of discussion in the text. Each lane contained 0.5 p.g of poly(dI-dC). (C) AP-1D factor. The
increased band intensity seen in lane 4 was highly irreproducible (see Table 4), in contrast to the differences seen in panel B. In panels C and
D, 0.25 ,ug of poly(dI dC) was used as nonspecific competitor. Arrows indicate the specific complexes. (D) AP-1p factor, analysis as for panel
C.
oligonucleotide showed homologous competition (lanes 11
and 12) but did not compete for the AP-lp complex (lanes 3
and 4). The quantitative reciprocity of these effects, as
measured at 100- and 200-fold molar excess, rules out the
trivial explanation that the two factors had identical speci-
ficities but were present at different concentrations in the
nuclear extract. These results show that the two AP-1
factors are distinct both in size and in specificity. As
discussed below, they are also distinct in regulation.
Constitutive factors. Two of the factors detected by these
assays appeared to be expressed constitutively in the
EL4.E1 thymoma cells. One, unexpectedly, was NFAT-1. A
complex of the expected mobility (indicated by an arrow in
Fig. 4A) was highly inducible in Jurkat cells (Fig. 4A, lanes
TABLE 4. Summary of effects of different stimulation conditions on specific IL-2 DNA-binding proteins
DNA-binding Stimulation conditionsa No. of
factor U T T/A T/A+I T/A+F exptsb
NFAT-1 +/-- + + + + + 2(D) + 3(C)
NF-KBC - ++ +±+ ++I+ +++ ++/+ 2(D) + 2(C)
AP lDc + + + + + + 2(D) + 2(C)
AP1lpC ±1- + - ++ +++ +++ 2(D) + 2(C)
a Terminology as in the legend to Fig. 4.
b Number of independent experiments (separate stimulation and extract preparation), counting separately cases in which extracts were generated by the method
of Dignam et al. (6) (D) or Crabtree (4) (C). Similar relative results were obtained with both kinds of extracts although the absolute concentrations of different
factors were somewhat different for the two protocols.
c One set of data was obtained from an experiment with extracts prepared by the method of Dignam et al. (6) which compared only the U, T, T/A, and T/A+ 1
conditions of culture.
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1 and 2). However, the corresponding complex was present
at indistinguishable levels in nuclear extracts from our
subline of EL4.E1 cells, whether or not they were stimulated
and regardless of the stimulation conditions used (Fig. 4A,
lanes 4 to 9). This complex appeared unlikely to represent a
spurious DNA-binding activity, since it was specific by the
competition assays in Fig. 3 but quantitatively unaffected by
increasing the concentration of nonspecific competitor (Fig.
4A, lanes 3 and 6). Thus, although the NFAT-1 site appeared
essential for expression, on the basis of our deletion studies,
the presence of its binding factor was not sufficient to
support IL-2 expression.
The other factor present at unchanged levels was the
complex of well-defined mobility binding the AP-1D site (Fig.
4C). This factor exhibited slight fluctuations in concentration
in different samples, but no reproducible increase was ob-
served upon stimulation under any conditions (Table 4). In
fact, in some experiments there was an indication that its
concentration diminished in stimulated cells. The possibility
that it might exert a negative regulatory effect is under
further study.
Inducible factors. Only two of the candidate inducible
factors showed increased DNA binding in response to induc-
tion. These were NF-KB (Fig. 4B) and the factor binding the
AP-lp site (Fig. 4D). In agreement with the ability of EL4.E1
cells to make IL-2 in response to TPA alone (Table 1), both
were activated in cells stimulated with TPA alone (Fig. 4B
and D, lanes 2). The further addition of A23187 up regulated
both binding activities in most experiments, in accord with
its effect on IL-2 production (Table 1), although the extents
of up regulation did not match precisely (Fig. 4B and D;
compare lanes 2 and 4). The binding activities of both
factors, however, were reproducibly enhanced further by
addition of IL-1, which consistently yielded the highest
levels observed of both complexes (Fig. 4B and D, lanes 5).
This result was not due to additive activation of these factors
by IL-1 and by TPA + A23187, for in most experiments IL-1
alone induced little or no binding activity of either type
(compare lanes 3 in Fig. 4B and D). Thus, while IL-1 was
only marginally and irreproducibly capable of activating
either binding factor alone, it was a potent enhancer of the
stimulating capacity of A23187 and TPA.
Summary. The results of multiple analyses of these four
factors are collated in Table 4. Overall, these data agree
plausibly with the IL-2 titers reported in Table 1, if it is
assumed that all four factors are required for optimal pro-
moter activity. The surprising, constitutive expression of
NFAT-1 in this subline of cells, and possibly that of the
AP-1D binding factor a well, may simply provide the
biochemical explanation For the unique ability of EL4.E1
cells to express IL-2 in response to TPA alone. Neverthe-
less, this set of factors may not be sufficient to account for all
regulatory modulation of IL-2 gene expression in EL4.E1
cells. As shown previously (Novak and Rothenberg, in
press; Tables 1 and 3), 10' M forskolin inhibits IL-2
induction by two- to threefold under these conditions. It is
therefore surprising that forskolin, when added to TPA and
A23187, induced effects on these DNA-binding proteins that
were very similar to those of IL-1 (Fig. 4A, lane 9; Fig. 4B to
D, lanes 6). While in several experiments the addition of
forskolin appeared to decrease NF-KB expression selec-
tively (data not shown), this effect was often modest (e.g.,
Fig. 4B). It is thus possible that the ratio of AP-lp to NF-KB
affects expression. However, it seems more likely that the
activity of the four putative positive regulators can be
influenced by other regulatory proteins not examined here.
Preliminary results suggest that the net inhibitory effects of
elevated cAMP depend on the presence of additional dis-
crete sequences in the IL-2 regulatory region (P. M. White
and E. V. Rothenberg, unpublished results).
DISCUSSION
IL-1 has a long history as a costimulator of T-cell re-
sponses (9, 13, 25, 44). In recent years, it has become clear
that this cytokine carries out different essential functions,
depending on the cell type being stimulated. Most effects of
IL-1 on mature T cells, however, can be substituted for by
the addition of phorbol esters, presumably via stimulation of
protein kinase C. Biochemical evidence does not support the
conclusion that IL-1 acts directly via protein kinase C (1),
but in most cases activation of this kinase can obscure the
effects of IL-1 itself on T cells. In this study we took
advantage of the unusual properties of EL4.E1 cells, which
respond to IL-1 as a costimulus even with optimal levels of
TPA, to investigate the molecular mediators by which IL-1
can cooperate with the phosphoinositide pathway. Our re-
sults show that IL-1 costimulates IL-2 gene expression by
enhancing the activity of the IL-2 gene promoter, correlated
with augmented levels of an NF-KB-like factor and one of
two distinct AP-1-like factors that bind to IL-2 regulatory
sequences.
Recent work by Shirakawa and colleagues has shown that
IL-1 can utilize cAMP as an intracellular second messenger
for the induction of K immunoglobulin light-chain synthesis
in the mouse pre-B-cell line 70Z/3 (42). In these cells,
IL-1-mediated induction coincides with the activation of a
protein that can bind to the NF-KB consensus site in the
5'-flanking region of the K-chain genes (40). NF-KB is not the
only transcription factor implicated in IL-1 effects, however.
IL-1 can also induce transcription of the c-jun proto-onco-
gene, which encodes a component of AP-1, in the mouse
IL-1-dependent T-cell line LBRM-331A5 (26). In that cell
line, expression of a linked reporter gene from the human
IL-2 promoter required an intact AP-1 site at -185 relative
to the transcriptional start site. However, the deletions
tested which removed this site also removed the NF-KB site
centered at -200. Therefore, the resulting loss of promoter
function (26) cannot be attributed unequivocally to loss of
this distal AP-1 site. In fact, deletion analysis of the human
IL-2 gene promoter has not demonstrated an important role
for this AP-1 site in vivo (8). Footprint analysis of the mouse
IL-2 promoter has led to the same conclusion (37).
In several respects, our results are in agreement with these
previous reports. Thus, our data support the interpretation
that one mediator of the IL-1 effect may be NF-KB or a
related factor (31, 40). The addition of IL-1 as a costimulus
invariably augmented NF-KB binding activity over that
induced by the cocktail of TPA and A23187, and in some
experiments (e.g., Fig. 4) we could even detect enhanced
NF-KB binding after stimulation with IL-1 alone. As ex-
pected if IL-1 activated NF-KB, it also enhanced the induc-
tion of IL-2 receptor a-chain transcripts in the EL4.E1 cells
(T. J. Novak and E. V. Rothenberg, unpublished results).
Even the failure of IL-1 to affect IL-2 gene promoter activity
in Jurkat cells is also consistent with its working through
NF-KB, since in these cells IL-1 does not induce appearance
of this DNA-binding protein (31). The resulting implication
that NF-KB may be rate limiting for IL-2 induction is in
accord with published evidence that mutation of the NF-KB
site depresses IL-2 gene promoter function, relative to wild
type, in optimally stimulated cells (17).
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In contrast to other cell types (41, 42), however, EL4.E1
cells appear to be able to respond to IL-1 as a costimulus
without using cAMP as the principal mediator. As we report
here and in more detail elsewhere (Novak and Rothenberg,
in press), IL-2 gene promoter activity is significantly inhib-
ited by treatments that cause a sustained elevation of intra-
cellular cAMP. This inhibition is especially sharp at the early
times when IL-1 is most potent in its stimulatory activity.
Thus, the cooperative effects of IL-1 with phosphoinositide
pathway stimulation and those of cAMP appear quite dis-
tinct.
It seems paradoxical, then, that both IL-1 and cAMP may
enhance activation of NF-KB. Indeed, both also hyperacti-
vate the binding factor of the proximal AP-1 site. However,
while the induced DNA-binding activities that we have
studied probably participate in the mechanism regulating
IL-2 gene promoter activity, they may not be the only
components, or the only decisive components, of a combi-
natorial mechanism. The resolution of this paradox is most
likely to come, therefore, from more extensive monitoring of
the ensemble of regulatory proteins that control IL-2 gene
expression, rather than a focus on any single one. Our
results with only four such factors provide compelling evi-
dence for the combinatorial nature of IL-2 gene regulation.
The NFAT-1 factor, the regulation of which may be suffi-
cient to account for the response to TcR ligands in Jurkat
cells (4, 10) is not rate limiting in EL4.E1 cells. The
NFAT-1-binding activity is present at maximal levels even in
cells which cannot secrete IL-2 and cannot express IL-2
promoter constructs. Yet the cooperation of this factor
appears to be required for efficient IL-2 induction, as shown
by the minimal activity, with or without IL-1, of constructs
from which its binding site has been deleted. In this context,
the shared abilities of forskolin and IL-1 to stimulate the
AP-lp factor and NF-KB imply less that these agents mediate
the same signal than that the set of factors we monitor may
be incomplete.
How can the costimulatory effects of IL-1 on AP-lp and
NF-KB activation be explained? There are two general
possibilities. First, IL-1/IL-1R triggering may directly induce
activation of these two factors, and possibly others uniquely
responsive to IL-1, mobilizing pools that are not accessible
to the calcium ionophore/phorbol ester stimulation pathway.
The effects of IL-1 would then be additive with those of the
phosphoinositide pathway agonists, at the level of the DNA-
protein contacts in chromatin. Another possibility is that the
ability of A23187/TPA to activate these DNA-binding pro-
teins is itself modulated by an intracellular gating function
that is subject to IL-1 regulation. In this case, IL-1 need not
induce any DNA-binding protein activities by itself in order
to be a potent regulator of the efficiency with which the
major activating pathway mobilizes gene expression. While
too few factors have yet been examined to confirm or rule
out the first mechanism, several of our findings lend plausi-
bility to the second. First, IL-1 alone is strikingly poor at
effecting any increase or decrease in the binding activity of
any of the factors studied here. In EL4.E1 cells, it is far
more potent as a costimulus than as a stimulus (see, e.g.,
Table 4). Second, the factors that IL-1 coactivates thus far
appear to be only those that are activated in any case by
A23187 and TPA. Third, our survey of IL-1 effects on the
expression of IL-2 promoter constructs with widely differing
numbers of positive and negative modulatory sites (30)
indicates that all expressible constructs are affected in par-
allel. Thus, IL-1 may act in these cells by enhancing the
potency of A23187 and TPA as inducing agents, its signals
converging with the phosphoinositide pathway before the
activation of the specific DNA-binding proteins.
The mechanism of IL-1 costimulation may help to illumi-
nate key stages in the development of T-cell functional
competence. We have previously reported that immature
thymocytes can activate the IL-2 gene, but only subject to an
absolute requirement for IL-1 costimulation. The locus of
the IL-1 effect may thus identify a stage-specific block to the
exercise of function in immature cells which is later over-
come by the complex physiology of positiv,e~selection in the
thymus. Work is now under way to explo#e this possibility.
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